AcuraStem, Inc. is a privately held, patient-based biotechnology company headquartered in Monrovia, California, developing therapeutics for neurodegenerative diseases including sporadic ALS (amyotrophic lateral sclerosis) and frontotemporal dementia (FTD). The company's proprietary iNeuroRx drug-discovery platform builds disease models from induced pluripotent stem cells (iPSC) taken from individual patients, in place of animal models, and pairs them with machine-learning analysis to identify and validate targets. Its lead antisense oligonucleotide candidate, AS-241 (PIKFYVE), is advancing toward first-in-human testing with California Institute for Regenerative Medicine (CIRM) grant support. AcuraStem is a therapeutics developer rather than a software vendor: it publishes no public API, developer portal, SDK, or machine-readable contract of any kind. This profile records that absence with the probe evidence behind it.
AcuraStem is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Life Sciences, and Drug Discovery.
AcuraStem’s developer surface includes engineering blog and 9 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/acurastem: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: acurastem
name: AcuraStem
description: 'AcuraStem, Inc. is a privately held, patient-based biotechnology company headquartered in Monrovia, California,
developing therapeutics for neurodegenerative diseases including sporadic ALS (amyotrophic lateral sclerosis) and frontotemporal
dementia (FTD). The company''s proprietary iNeuroRx drug-discovery platform builds disease models from induced pluripotent
stem cells (iPSC) taken from individual patients, in place of animal models, and pairs them with machine-learning analysis
to identify and validate targets. Its lead antisense oligonucleotide candidate, AS-241 (PIKFYVE), is advancing toward first-in-human
testing with California Institute for Regenerative Medicine (CIRM) grant support. AcuraStem is a therapeutics developer
rather than a software vendor: it publishes no public API, developer portal, SDK, or machine-readable contract of any kind.
This profile records that absence with the probe evidence behind it.'
url: https://raw.githubusercontent.com/api-evangelist/acurastem/refs/heads/main/apis.yml
image: https://acurastem.com/application/files/7516/7235/4056/acs_logo_notag.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Therapeutics
- Life Sciences
- Drug Discovery
- Neuroscience
- Neurodegenerative Disease
- ALS
- Stem Cells
- Machine Learning
- Private Company
tags_raw:
- Company
- Biotechnology
- Therapeutics
- Life Sciences
- Drug Discovery
- Neuroscience
- Neurodegenerative Disease
- ALS
- Stem Cells
- Machine Learning
- Private Company
- Machine-Learning
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/acurastem-domain-security.yml
- type: LLMsTxt
url: llms/acurastem-llms.txt
- type: Website
url: https://acurastem.com/
- type: About
url: https://acurastem.com/about-us
- type: Blog
url: https://acurastem.com/blog
- type: Newsroom
url: https://acurastem.com/media
- type: Careers
url: https://acurastem.com/careers
- type: PrivacyPolicy
url: https://acurastem.com/privacy-policy
- type: LinkedIn
url: https://www.linkedin.com/company/12903559/
- type: X
url: https://x.com/acurastem
x-enrichment:
date: '2026-09-06'
status: minimal
artifacts_added: 3
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: AcuraStem is a preclinical ALS/FTD therapeutics developer whose entire public web presence is a six-page Concrete
CMS 9.5.2 marketing site (about, science, therapeutics, media, careers) with no developer, API, or data-access section,
no API subdomain resolving in DNS, and an empty GitHub organization with zero public repositories.
evidence:
- url: https://acurastem.com/
status: 200
- url: https://acurastem.com/openapi.json
status: 404
- url: https://acurastem.com/.well-known/api-catalog
status: 404
- url: https://acurastem.com/llms.txt
status: 404
- url: https://acurastem.com/sitemap.xml
status: 200
- url: https://api.github.com/orgs/acurastem
status: 200
checked: '2026-09-06'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.